Peptide-Polymer-Lipid Conjugate Nanoparticles for Monodisperse Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing nanoparticles for biomedical and pharmaceutical applications, such as liposomes and synthetic virus-like nanoparticles, face challenges in achieving monodispersity, stability at room temperature, and cost-effectiveness, particularly in forming particles with diameters in the range of tens of nanometers.
Innovation Solution
The development of peptide-polymer-lipid conjugates that self-assemble into helix bundles and subsequently form nanoparticles with diameters between 10-20 nm, which can encapsulate therapeutic or diagnostic agents, using a peptide with a helical structure covalently linked to a polymer and a hydrophobic moiety, allowing for controlled size and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If liposomes are used as nanoparticles, then a wide range of sizes down to 20-30 nm can be achieved, but the formation process is not instantaneous and involves multi-step procedures such as sonication and extrusion
Solution Approach 1:
The patent employs self-assembling peptide amphiphiles that automatically form nanoparticles through spontaneous assembly in aqueous solutions, eliminating the need for complex multi-step procedures like sonication and extrusion. The amphiphilic molecules naturally organize into monodisperse nanoparticles with controlled sizes, achieving both manufacturing precision and process simplicity.
2Manufacturing precision
If synthetic virus-like nanoparticles are made using recombinant proteins, then 20-100 nm diameter nanoparticles can be produced, but extensive purification is required to remove residual compounds
Solution Approach 1:
The patent uses chemically synthesized peptide amphiphiles instead of recombinant proteins, eliminating the need for extensive purification steps. The peptides are synthesized with precise control over their sequences and structures, allowing direct formation of nanoparticles without residual contamination issues, thereby simplifying the manufacturing process while maintaining diameter control.
3Adaptability or versatility
If synthetic virus-like nanoparticles are made using recombinant proteins, then nanoparticles with antigenic peptides can be produced, but refrigeration is required to prevent protein denaturation
Solution Approach 1:
The patent creates composite structures by incorporating antigenic peptide sequences within the stable peptide amphiphile framework. The hydrophobic tails and helical structures provide thermal stability while the antigenic sequences maintain their functional display, achieving both versatility and stability without requiring refrigeration.
4Ease of manufacture
If polymeric nanoparticles are produced, then particles can be formed, but they tend to give large particles with limited reports of 10-20 nm size range
Solution Approach 1:
The patent achieves precise control over nanoparticle size in the 10-20 nm range by carefully adjusting parameters of the peptide amphiphile structure, including the length and composition of hydrophobic tails, the sequence of hydrophilic headgroups, and the overall molecular weight. These parameter optimizations enable small particle formation while maintaining ease of manufacture through self-assembly.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide-polymer-lipid conjugates enable the formation of stable, monodisperse nanoparticles that can effectively deliver therapeutic agents and maintain structural integrity at room temperature, addressing the limitations of existing technologies while offering enhanced stability and cost-effectiveness.
Implementation Method 1
The development of peptide-polymer-lipid conjugates that self-assemble into helix bundles and subsequently form nanoparticles
Implementation Method 2
a hydrophobic moiety covalently linked to the N-terminus of the peptide
Data Source
AI summary
The present invention provides a conjugate having a peptide with from about 10 to about 100 amino acids, wherein the peptide adopts a helical structure. The conjugate also includes a first polymer covalently linked to the peptide, and a hydrophobic moiety covalently linked to the N-terminus of the peptide, wherein the hydrophobic moiety comprises a second polymer or a lipid moiety. The present invention also provides helix bundles form by self-assembling the conjugates, and particles formed by self-assembling the helix bundles. Methods of preparing the helix bundles and particles are also provided.